Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation

Next Previous
X
Search
Trial Profile

Positron Emission Tomography (PET) Imaging of Paediatric Patients with High-Risk Neuroblastoma Using 64Cu-SARTATE: A Multi-Centre, Open-Label, Non-Randomised, Phase-1 Imaging Investigation

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 64Cu-MeCOSar-Octreotate (Primary)
  • Indications Neuroblastoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Clarity Pharmaceuticals

    • Most Recent Events

    • 04 Dec 2018 Status changed to withdrawn prior to enrolment.
    • 14 Feb 2018 Planned initiation date changed from 25 Sep 2017 to 5 Mar 2018.
    • 08 Dec 2017 According to a Clarity Pharmaceuticals media release, Additional sites in Australia and the USA will be activated over the coming months in order to fast-track the completion of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top